

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address		Address	
City State ZIP		City State ZIP	
Main Phone	Alternate Phone	Phone	Fax
Social Security #		Contact Person	
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI # License #

Clinical Information			
Primary Diagnosis: <input type="checkbox"/> B20 HIV/AIDS <input type="checkbox"/> PREP; ICD-10: _____ <input type="checkbox"/> PEP; ICD-10: _____		Comorbidities: <input type="checkbox"/> B18.1 Hepatitis B (chronic) <input type="checkbox"/> B18.2 Hepatitis C (chronic) <input type="checkbox"/> R64: Cachexia (HIV wasting) <input type="checkbox"/> Other: _____	
CD4 Cell Count	Viral Load/HIV RNA	CrCl	Date of Lab
Is Patient Currently on Therapy: <input type="checkbox"/> No <input type="checkbox"/> Yes		Has Patient Been Treated Previously for this Condition: <input type="checkbox"/> No <input type="checkbox"/> Yes If Yes, Medication: _____	
Drug Allergies		Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs	Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Medication	Dose/Strength	Directions	Qty	Refills
Complete Regimens				
<input type="checkbox"/> Atripla®	600 mg-300 mg-200 mg Tablet	1 tablet by mouth once daily on empty stomach	_____	_____
<input type="checkbox"/> Biktarvy®	50 mg-25 mg-200 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Cabenuva®	<input type="checkbox"/> Oral Lead-In (Theracon distributed) (cabotegravir 30 mg tablet/ rilpivirine 25 mg tablet)	1 tablet by mouth once daily with food/ 1 tablet by mouth once daily with food	30 30	None None
	Every 2-Month Dosing <input type="checkbox"/> 600 mg-900 mg Injections	<input type="checkbox"/> Load: 2 injections intramuscularly on month 1 and 2, and 2 injections every 2 months thereafter <input type="checkbox"/> Maintenance: 2 injections intramuscularly every 2 months	1 Kit 1 Kit	1 Refill _____
	Once Monthly Dosing <input type="checkbox"/> Initiation Injections (600 mg-900 mg) <input type="checkbox"/> Continuation Injections (400 mg-600 mg)	2 injections intramuscularly, once 2 injections intramuscularly, monthly	1 Kit 1 Kit	None _____
<input type="checkbox"/> Complera®	25 mg-300 mg-200 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Delstrigo®	100 mg-300 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Dovato®	50 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Genvoya®	150 mg-150 mg-10 mg-200 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Juluca®	50 mg-25 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Odefsey®	25 mg-25 mg-200 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Stribild®	150 mg-150 mg-300 mg-200 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Symfi®	600 mg-300 mg-300 mg Tablet	1 tablet by mouth once daily on empty stomach	_____	_____
<input type="checkbox"/> Symfi Lo®	400 mg-300 mg-300 mg Tablet	1 tablet by mouth once daily on empty stomach	_____	_____
<input type="checkbox"/> Symtuza®	800 mg-150 mg-10 mg-200 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Triumeq®	50 mg-600 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address		Address	
City State ZIP		City State ZIP	
Main Phone	Alternate Phone	Phone	Fax
Social Security #		Contact Person	
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI # License #

Clinical Information	
Primary Diagnosis: <input type="checkbox"/> B20 HIV/AIDS <input type="checkbox"/> PREP; ICD-10: _____ <input type="checkbox"/> PEP; ICD-10: _____	Comorbidities: <input type="checkbox"/> B18.1 Hepatitis B (chronic) <input type="checkbox"/> B18.2 Hepatitis C (chronic)
CD4 Cell Count	Viral Load/HIV RNA
CrCl	Date of Lab
Is Patient Currently on Therapy: <input type="checkbox"/> No <input type="checkbox"/> Yes	Has Patient Been Treated Previously for this Condition: <input type="checkbox"/> No <input type="checkbox"/> Yes If Yes, Medication: _____
Drug Allergies	Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Medication	Dose/Strength	Directions	Qty	Refills
NRTI				
<input type="checkbox"/> Cimduo®	300 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Combivir®	300 mg-150 mg Tablet	1 tablet by mouth twice daily	_____	_____
<input type="checkbox"/> Descovy®	25 mg-200 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Emtriva®	<input type="checkbox"/> 200 mg Capsule <input type="checkbox"/> 10 mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Epivir®	<input type="checkbox"/> 100 mg Tablet <input type="checkbox"/> 150 mg Tablet <input type="checkbox"/> 300 mg Tablet <input type="checkbox"/> 5 mg/mL Solution <input type="checkbox"/> 10 mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Epzicom®	600 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Retrovir®	<input type="checkbox"/> 100 mg Tablet <input type="checkbox"/> 300 mg Tablet <input type="checkbox"/> 10 mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Temyxis®	300 mg-300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Truvada®	<input type="checkbox"/> 300-200 mg Tablet <input type="checkbox"/> 250-167 mg Tablet <input type="checkbox"/> 200-133 mg Tablet <input type="checkbox"/> 150-100 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Viread®	300 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Ziagen®	300 mg Tablet	<input type="checkbox"/> 1 tablet by mouth twice daily <input type="checkbox"/> 2 tablets by mouth once daily	_____	_____

NNRTI				
<input type="checkbox"/> Edurant®	25 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Intelence®	<input type="checkbox"/> 25 mg Tablet <input type="checkbox"/> 100 mg Tablet <input type="checkbox"/> 200 mg Tablet	_____	_____	_____
<input type="checkbox"/> Pifeltro®	100 mg Tablet	1 tablet by mouth once daily	_____	_____
<input type="checkbox"/> Sustiva®	<input type="checkbox"/> 50 mg Tablet <input type="checkbox"/> 200 mg Tablet <input type="checkbox"/> 600 mg Tablet	1 tablet by mouth once daily on empty stomach	_____	_____
<input type="checkbox"/> Viramune®	<input type="checkbox"/> 200 mg Tablet <input type="checkbox"/> 50 mg/5 mL Soln	_____	_____	_____
<input type="checkbox"/> Viramune XR®	<input type="checkbox"/> 100 mg Tablet <input type="checkbox"/> 400 mg Tablet	_____	_____	_____

Integrase Inhibitor				
<input type="checkbox"/> Isentress®	<input type="checkbox"/> 400 mg Tablet <input type="checkbox"/> 600mg Tablet	_____	_____	_____
<input type="checkbox"/> Tivicay®	50 mg Tablet	<input type="checkbox"/> For naive: 1 tablet by mouth once daily <input type="checkbox"/> For experienced: 1 tablet by mouth twice daily	_____	_____

Entry Inhibitor				
<input type="checkbox"/> Fuzeon®	90 mg/1 mL Soln	1 mL (90 mg) under the skin twice daily	_____	_____
<input type="checkbox"/> Rukobia®	600 mg Tablet	1 tablet by mouth twice daily	_____	_____
<input type="checkbox"/> Selzentry®	<input type="checkbox"/> 150 mg Tablet <input type="checkbox"/> 300 mg Tablet	_____	_____	_____

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

Need By Date: _____ Ship To: ☐ Patient ☐ Office ☐ Other _____ Fax Copy: ☐ Rx Card Front/Back ☐ Clinical Notes ☐ Medical Card Front/Back

Patient Information		Prescriber Information	
Patient Name		Prescriber Name	
Address		Address	
City State ZIP		City State ZIP	
Main Phone	Alternate Phone	Phone	Fax
Social Security #		Contact Person	
Date of Birth	<input type="checkbox"/> Female <input type="checkbox"/> Male	DEA #	NPI # License #

Clinical Information			
Primary Diagnosis: <input type="checkbox"/> B20 HIV/AIDS <input type="checkbox"/> PREP; ICD-10: _____ <input type="checkbox"/> PEP; ICD-10: _____		Comorbidities: <input type="checkbox"/> B18.1 Hepatitis B (chronic) <input type="checkbox"/> B18.2 Hepatitis C (chronic) <input type="checkbox"/> R64: Cachexia (HIV wasting) <input type="checkbox"/> Other: _____	
CD4 Cell Count	Viral Load/HIV RNA	CrCl	Date of Lab
Is Patient Currently on Therapy: <input type="checkbox"/> No <input type="checkbox"/> Yes		Has Patient Been Treated Previously for this Condition: <input type="checkbox"/> No <input type="checkbox"/> Yes If Yes, Medication: _____	
Drug Allergies		Weight <input type="checkbox"/> kg <input type="checkbox"/> lbs	Status: <input type="checkbox"/> New <input type="checkbox"/> Restart <input type="checkbox"/> Continuing

Medication	Dose/Strength	Directions	Qty	Refills
PK Booster				
<input type="checkbox"/> Norvir®	<input type="checkbox"/> 100 mg Tablet <input type="checkbox"/> 80mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Tybost®	150 mg Tablet	1 tablet by mouth once daily with food	_____	_____
Protease Inhibitors (PI)				
<input type="checkbox"/> Aptivus®	<input type="checkbox"/> 250 mg Capsule <input type="checkbox"/> 100 mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Crixivan®	<input type="checkbox"/> 400 mg Capsule	<input type="checkbox"/> 2 capsules by mouth every 8 hours on empty stomach <input type="checkbox"/> Take 2 capsules by mouth with NORVIR® twice daily	_____	_____
<input type="checkbox"/> Evotaz®	300 mg-150 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Kaletra®	<input type="checkbox"/> 100-25 mg Tablet <input type="checkbox"/> 200-50 mg Tablet <input type="checkbox"/> 80 mg-20 mg/mL Solution	_____	_____	_____
<input type="checkbox"/> Lexiva®	<input type="checkbox"/> 700 mg Tablet <input type="checkbox"/> 50 mg/mL Susp	_____	_____	_____
<input type="checkbox"/> Prezcobix®	800 mg-150 mg Tablet	1 tablet by mouth once daily with food	_____	_____
<input type="checkbox"/> Prezista®	<input type="checkbox"/> 75 mg Tablet <input type="checkbox"/> 150 mg Tablet <input type="checkbox"/> 600 mg Tablet <input type="checkbox"/> 800 mg Tablet <input type="checkbox"/> 100 mg/mL Susp	_____	_____	_____
<input type="checkbox"/> Reyataz®	<input type="checkbox"/> 150 mg Capsule <input type="checkbox"/> 200 mg Capsule <input type="checkbox"/> 300 mg Capsule <input type="checkbox"/> 50 mg Packet	_____	_____	_____
<input type="checkbox"/> Viracept®	<input type="checkbox"/> 250 mg Capsule <input type="checkbox"/> 625 mg Capsule	_____	_____	_____
PrEP Only Regimen				
<input type="checkbox"/> Apretude	<input type="checkbox"/> Oral Lead-In (Theracom distributed; optional) (cabotegravir 30 mg tablet)	1 tablet by mouth once daily with food	30	None
	<input type="checkbox"/> 600 mg Injection	<input type="checkbox"/> Load: 1 injection intramuscularly on month 1 and 2, then 1 injection every 2 months thereafter <input type="checkbox"/> Maintenance: 1 injection intramuscularly every 2 months	1 Kit 1 Kit	1 Refill _____
Growth Hormone				
<input type="checkbox"/> Egrifta SV®	2 mg Vial	Inject 1.4 mg under the skin once daily	30	_____
<input type="checkbox"/> Serostim®	<input type="checkbox"/> 4 mg Vial <input type="checkbox"/> 5 mg Vial <input type="checkbox"/> 6 mg Vial	Inject _____ mg under the skin once daily at bedtime	28	_____
Ancillary	<input type="checkbox"/> BD 3 mL 20 g x 1" Syringe <input type="checkbox"/> 30 g x 0.5" Needles	Use as directed with SEROSTIM®	QS	_____
Other				

By signing this form, you are authorizing BioPlus Specialty Pharmacy and its employees to serve as your designated agent in submitting clinical and other required information to third party payers with respect to this prescription and any refills or continuation of the same medication and dose for this patient. IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged property, or exempt from disclosure under applicable law. If you are not the named addressee you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.

Prescriber's Signature (no stamps) Substitution Permitted

Date

Prescriber's Signature (no stamps) Dispense As Written

Date

BSP250624